Drug Profile
Research programme: small molecule therapeutics - Avalon/Novartis
Latest Information Update: 19 Jul 2010
Price :
$50
*
At a glance
- Originator Avalon Pharmaceuticals; Novartis
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 19 Jul 2010 Discontinued for Undefined indication in USA (unspecified route)
- 21 Aug 2009 Development is ongoing in USA
- 29 May 2009 Avalon Pharmaceuticals has been acquired and merged into Clinical Data